Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
Know Labs, Inc., now reflected in SEC filings as USBC, Inc., reports developments tied to its completed control transaction, digital-asset treasury strategy and continuing diagnostic-technology work. Recent updates include the company's shift toward the USBC token, a digital U.S. dollar product using blockchain and digital identity, alongside governance, shareholder voting and capital-structure actions.
The company's legacy research division continues work on Radio Frequency Dielectric Spectroscopy (RFDS), a spectroscopy platform designed to capture molecular signatures in wearable, mobile or bench-top formats. News also covers non-invasive analyte monitoring, pH detection research, a planned non-invasive glucose-monitor application requiring FDA clearance, licensing activity through Know Labs Technology Licensing and public-company status changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Know Labs, Inc. (KNW) has announced successful results from a proof-of-principle study demonstrating the accuracy of its proprietary Bio-RFID technology in non-invasive medical diagnostics. Conducted in collaboration with Mayo Clinic, the study, titled "Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions," showcased a remarkable 100% accuracy rate in measuring various analytes in vitro. This breakthrough technology captures molecular signatures using radio waves, with glucose monitoring being its first application. Market trends highlighting the need for affordable, accurate non-invasive healthcare solutions further bolster the significance of these results. The full study awaits peer-review publication.
Know Labs, Inc. (NYSE American: KNW) has formed a new Scientific Advisory Board (SAB) featuring leading experts in medical technology and human health. This board aims to enhance Know Labs' efforts in algorithm refinement, device development, and clinical trial design for its Bio-RFID technology, which aims to offer non-invasive glucose monitoring. The SAB includes esteemed members like Dr. Benjamin Smarr and Dr. Mark Aloia, who bring extensive backgrounds in research and technology. Know Labs emphasizes 2023 as a year of prioritizing external validation of its non-invasive diagnostic technology.